Best supportive care in combination with polychemotherapy versus best supportive care alone as second-line therapy in stage IV metastatic melanoma (DeCOG MM-PAL 8)

被引：0
|
作者：
Ulrich, J.
Trefzer, U.
Tilgen, W.
Schadendorf, D.
Kaatz, M.
Mohr, P.
Garbe, C.
Hauschild, A.
机构：
[1] Med Ctr, Quedlinburg, Germany
[2] Univ Berlin Charite, Berlin, Germany
[3] Univ Saarland, Homburg, Germany
[4] German Canc Res Ctr, Mannheim, Germany
[5] Univ Med Ctr, Jena, Germany
[6] Med Ctr, Buxtehude, Germany
[7] Univ Med Ctr, Tubingen, Germany
[8] Univ Med Ctr, Kiel, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8567
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase III study of pembrolizumab (pembro) versus best supportive care (BSC) for second-line therapy in advanced hepatocellular carcinoma (aHCC): KEYNOTE-240 Asian subgroup
    Kudo, Masatoshi
    Lim, Ho Yeong
    Cheng, Ann-Lii
    Chao, Yee
    Yau, Thomas
    Ogasawara, Sadahisa
    Kurosaki, Masayuki
    Morimoto, Naoki
    Ohkawa, Kazuyoshi
    Yamashita, Tatsuya
    Lee, Kyung-Hun
    Chen, Erluo
    Siegel, Abby B.
    Ryoo, Baek-Yeol
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [22] COST-EFFECTIVENESS COMPARISON OF BOTULINUM TOXIN TYPE A PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE IN THE TREATMENT OF IDIOPATHIC OVERACTIVE BLADDER WITH URINARY INCONTINENCE AMONG PATIENTS NOT ADEQUATELY MANAGED BY ANTICHOLINERGIC THERAPY IN FRANCE
    Ruffion, A.
    Velard, M.
    Loveman, C.
    Khalaf, K.
    Roze, S.
    Pignata, M.
    Stanisic, S.
    Lister, J.
    VALUE IN HEALTH, 2014, 17 (07) : A470 - A470
  • [23] Pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: Randomized, phase 3 KEYNOTE-240 study
    Finn, R.
    Chan, S. L.
    Zhu, A. X.
    Knox, J.
    Cheng, A-L.
    Siegel, A.
    Bautista, O.
    Watson, P. A.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [24] Phase 3, randomized KEYNOTE-240 study of pembrolizumab (Pembro) versus best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)
    Chan, S. L.
    Finn, R. S.
    Zhu, A. X.
    Knox, J.
    Cheng, A-L.
    Siegel, A. B.
    Bautista, O.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [25] Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    Thuss-Patience, Peter C.
    Kretzschmar, Albrecht
    Bichev, Dmitry
    Deist, Tillman
    Hinke, Axel
    Breithaupt, Kirstin
    Dogan, Yasemin
    Gebauer, Bernhard
    Schumacher, Guido
    Reichardt, Peter
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (15) : 2306 - 2314
  • [26] Phase 3 randomized study for evaluation of physician choice Rx versus best supportive care as second-line or beyond therapy in head and neck cancer with poor performance status.
    Karpe, Ashay
    Patil, Vijay Maruti
    Bhosale, Bharatsinha Baburao
    Noronha, Vanita
    Prabhash, Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA6019 - LBA6019
  • [27] A phase II study of geftinib versus best supportive care as second or third line therapy in advanced squamous cell carcinoma of lung in Asian Indians
    Kumar, N.
    Kapoor, A.
    Kalwar, A.
    Kumar, A.
    Narayan, S.
    Lal, S.
    Beniwal, S. K.
    ANNALS OF ONCOLOGY, 2015, 26 : 138 - 138
  • [28] THE COST EFFECTIVENESS OF CETUXIMAB PLUS BEST SUPPORTIVE CARE (BSC) VERSUS BSC ALONE IN LAST LINE FOR KRAS WILD TYPE METASTATIC COLORECTAL CANCER PATIENT POPULATION
    Chaugule, S.
    Hay, J.
    VALUE IN HEALTH, 2012, 15 (04) : A219 - A219
  • [29] A multicenter, randomized phase III trial comparing second-line chemotherapy (SLC) plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC)
    Park, S. H.
    Lim, D. H.
    Park, K.
    Lee, S.
    Oh, S. Y.
    Kwon, H.
    Kang, J. H.
    Hwang, I. G.
    Lee, J.
    Park, J. O.
    Park, Y. S.
    Lim, H. Y.
    Kang, W. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer
    Evans, WK
    LeChevalier, T
    EUROPEAN JOURNAL OF CANCER, 1996, 32A (13) : 2249 - 2255
12345